No more Covishield vaccines will arrive in the country and they evaluate how to replace the second dose

Foreign Minister Felipe Solá confirmed this Thursday that India will not comply with the shipment of 580 thousand vaccines against the coronavirus manufactured by Covishield to which it had informally committed months ago in dialogue with Argentine authorities.

“India had a spectacular growth in infections and withheld all the vaccines produced. The ambassador came to explain that to me. He told me that they have an impressive stock, but that they need it to give a strong boost to the local vaccination campaign, “said the Minister of Foreign Affairs in a report for El Uncover radio.

Indeed, the COVID-19 pandemic in the Asian country, where record numbers of more than 370,000 daily cases are being recorded (more than a third of the global total), is “heartbreaking,” said Tedros Adhanom Ghebreyesus, the head of the government, yesterday. of the World Health Organization (WHO), in a press conference to ask for help to the Asian country where 1.3 billion people live.

The decision to discontinue the export of inoculants raised a question mark in Argentina. It is that the committed doses – which for now are not going to arrive – were going to be used to complete the vaccination scheme of people who were immunized at the end of February and that should be called again before the end of May according to the scheme of deferral approved by the Federal Health Committee.

Is it possible to replace the second dose with another vaccine?

“The vaccine that comes from India is Covishield, which is the same one manufactured by AstraZeneca. It is another brand, but the technology is the same. There should be no inconvenience in applying the second dose, “said doctor Lautaro de Vedia.

The doctor and head of the Infant Infectology Service, Enrique Casanueva, agreed: “I am not aware of any published work on interchangeability, but if one is based on other vaccines such as hepatitis, it could theoretically work, especially with vaccines with similar platforms.”

The problem that emerges for this solution is that AstraZeneca has also shown difficulties in meeting its commitments to the Argentine government. In fact, the laboratory recently issued a statement to respond to the discomfort of some authorities.

The specialists consulted agree that it would not be advisable to use vaccines from Sputnik, Pfizer or any other laboratory to complete the Covishield vaccination scheme because they use different technologies. “There are no studies to support it; it would be dangerous or not effective. It has no scientific endorsement. The vaccines are formulated on different platforms. I don’t recommend it, ”De Vedia said.

The Indian Vaccine

The Covishield vaccine is a variant of the one manufactured by AstraZeneca and Oxford, which is produced at the Serum Institute in India from a collaboration agreement in the context of a technology transfer from the Anglo-Swedish laboratory and the British university.

In late December, the National Administration of Drugs, Food and Medical Technology (ANMAT) validated the emergency use of the two-dose Oxford / AstraZeneca AZD1222 vaccine. This vaccine, the first created against SARS-COV-2 in the world after the outbreak of the pandemic, serves for the active immunization of people over 18 years of age with two doses administered with an interval of between 4 and 12 weeks, as recommended in the first place the English regulatory agency (MHRA) when authorizing it as an emergency supply.

For this, he assured that Phase III clinical trials demonstrated that this regimen is safe and effective in preventing symptomatic COVID-19, without serious cases or hospitalizations more than 14 days after the second dose, with which 82% of protection.

Source: Infobae

window.fbAsyncInit = function() {
appId: “128555857253291”,
xfbml: true,
version: “v2.6”


(function(d, s, id){
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) { return; }
js = d.createElement(s); = id;
js.src = “”;
fjs.parentNode.insertBefore(js, fjs);
}(document, ‘script’, ‘facebook-jssdk’));


Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more

Leave a Reply